2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as FXR modulators against dyslipidemia and related diseases

Details for Australian Patent Application No. 2009296048 (hide)

Owner F. Hoffmann-La Roche AG

Inventors Benson, Gregory Martin; Bleicher, Konrad; Grether, Uwe; Kuhn, Bernd; Richter, Hans; Taylor, Sven

Agent Spruson & Ferguson

Pub. Number AU-A-2009296048

PCT Pub. Number WO2010/034649

Priority 08165145.7 25.09.08 EP

Filing date 15 September 2009

Wipo publication date 1 April 2010

International Classifications

C07D 231/56 (2006.01) Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings

A61K 31/416 (2006.01) - condensed with carbocyclic ring systems, e.g. indazole

A61P 3/06 (2006.01) Drugs for disorders of the metabolism

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 403/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

Event Publications

28 April 2011 PCT application entered the National Phase

  PCT publication WO2010/034649 Priority application(s): WO2010/034649

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009296051-Transgenic plants with increased yield

2009296047-Pyridinylpiperazin derivatives useful as modulators of dopamine D3 receptors